ABSTRACT
To compare subfoveal choroidal thickness (SFCT) between cases with non-neovascular age-related macular degeneration ( AMD) and neovascular AMD by optical coherence tomography ( OCT ) and to evaluate the contribution of choroidal thickness (CT) measurements to the understanding of pathogenesis of neovascularization in AMD. ●METHODS: Fourty - eigth eyes of 24 patients who had neovascular AMD in one eye and non- neovascular AMD in the other eye were included in this retrospective, cross-sectional study as study group. Forty eyes of healthy,age and axial length matched individuals were selected as the control group. Eyes with drusen and/ or pigmentary changes were included in the non - neovascular AMD subgroup. Eyes with subretinal or intraretinal fluid and/orlipid exudation due to the choroidal neovascularization were included in the neovascular AMD subgroup. OCT measurements were performed with RTVue 100-2 (V 5. 1, Optovue, Fremont, CA, USA) perpendicularly from the outer part of the hyperreflective line ( retinal pigment epithelial layer) to the line corresponding to the choroido-scleral junction. Choroidal thickness was measured at 7 different points, 500μ m intervals up to 1500μ m temporal and nasal to the fovea in the study group and compared statistically between subgroups. ●RESULTS: The mean age of patients was 72. 4±8. 97 (60-82)y. The mean age of healthy individuals was 71. 2±8. 8 (58- 81) y. Mean SFCT of neovascular AMD group were significantly thicker than non- neovascular AMD group (P0. 05). ln neovascular AMD group, there was a statistically significant difference between the mean SFCT and the mean temporal-nasal choroid thickness (P ●CONCLUSlON: Choroidal thickness measurements with OCT device can make a contribution to the understanding the phatophysiology of AMD and large prospective studies should be conducted to understand why SFCT was thicker in neovascular AMD.
ABSTRACT
PURPOSE: To investigate the inflammation of the anterior chamber after intravitreal bevacizumab injection in different ocular exudative diseases. METHODS: The study included 76 eyes from 62 consecutive patients with different ocular exudative diseases. The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). The study also included 32 age-matched control patients. Inflammation of the anterior chamber was examined with flare-cell photometry before and after an intravitreal injection of 1.25 mg of bevacizumab. RESULTS: There were no statistically significant differences between the measurements at baseline and postoperative day 1, 3, 7, or 30 in any of the groups (p>0.05). CONCLUSIONS: The extent of inflammation in the anterior chamber did not change after intravitreal bevacizumab injection in patients with nonproliferative diabetic retinopathy, choroidal neovascularization secondary to age-related macular degeneration, or macular edema due to branch or central vein occlusion.
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Anterior Chamber/pathology , Antibodies, Monoclonal/administration & dosage , Iritis/diagnosis , Retinal Diseases/drug therapy , Aged , Angiogenesis Inhibitors/adverse effects , Anterior Chamber/drug effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal, Humanized , Bevacizumab , Choroidal Neovascularization/drug therapy , Diabetic Retinopathy/drug therapy , Exudates and Transudates , Female , Glucocorticoids/therapeutic use , Humans , Intravitreal Injections , Iritis/chemically induced , Iritis/drug therapy , Lasers , Macular Degeneration/drug therapy , Macular Edema/drug therapy , Male , Photometry , Retinal Vein Occlusion/drug therapy , Vascular Endothelial Growth Factor A/antagonists & inhibitorsABSTRACT
Tumor necrosis factor-alpha (TNF-alpha) antagonists have been successfully used in refractory cases of pediatric uveitis.(1-7) We report our experience with the monoclonal anti-TNF-alpha antibody infliximab in the treatment of uveitis in 20 children. Twenty children with noninfectious uveitis were treated with infliximab as an initial line of immunomodulatory therapy (4 children) or for uncontrolled intraocular inflammation despite aggressive immunosuppressive therapy (16 children). Intraocular inflammation was controlled in the short term in all children; resistance developed in 4 children after long-term therapy.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Antibodies, Monoclonal/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Uveitis/drug therapy , Adolescent , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/adverse effects , Child , Child, Preschool , Drug Administration Schedule , Drug Resistance , Female , Humans , Infliximab , Male , Retrospective Studies , Treatment OutcomeABSTRACT
A 27-year-old white woman presented with enophthalmos in the right eye. The visual acuity was 20/20 in both eyes. External examination showed 7 mm of enophthalmos of the right eye with deepened superior palpebral sulcus compared with the left eye. After Valsalva maneuver, the right eye became 4-mm exophthalmic compared with the left eye. Extraocular movements were full. There was no palpable orbital mass or diplopia. MRI showed diffuse enhancing intraconal orbital and nasopharyngeal masses consistent with venous malformations in the right orbit. Systemic evaluation revealed bluish vascular lesions on the hard and soft palates, and the pretibial area of her right leg. These findings were suggestive of blue rubber bleb nevus syndrome. The patient was observed, and her clinical findings remained stable for 12 months. Enophthalmos can be a rare initial presentation of blue rubber bleb nevus syndrome and patients with ophthalmic involvement should undergo systemic evaluation including gastrointestinal, dermatologic, and otorhinolaryngologic examination.
